# reload+after+2024-01-21 04:47:49.112153
address1§2916 North Miami Avenue
address2§Suite 1000
city§Miami
state§FL
zip§33127
country§United States
phone§305 509 6897
website§https://verupharma.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
fullTimeEmployees§189
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Mitchell S. Steiner F.A.C.S., M.D.', 'age': 62, 'title': 'Chairman, President & CEO', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 1519997, 'exercisedValue': 0, 'unexercisedValue': 14640310}, {'maxAge': 1, 'name': 'Dr. Harry  Fisch F.A.C.S., M.D.', 'age': 64, 'title': 'Vice Chairman & Chief Corporate Officer', 'yearBorn': 1959, 'fiscalYear': 2022, 'totalPay': 708811, 'exercisedValue': 0, 'unexercisedValue': 5692011}, {'maxAge': 1, 'name': 'Dr. K. Gary Barnette Ph.D.', 'age': 55, 'title': 'Chief Scientific Officer', 'yearBorn': 1968, 'fiscalYear': 2022, 'totalPay': 904146, 'exercisedValue': 0, 'unexercisedValue': 6200912}, {'maxAge': 1, 'name': 'Ms. Michele  Greco', 'age': 64, 'title': 'CFO & Chief Administrative Officer', 'yearBorn': 1959, 'fiscalYear': 2022, 'totalPay': 659625, 'exercisedValue': 0, 'unexercisedValue': 4374940}, {'maxAge': 1, 'name': 'Mr. Samuel  Fisch', 'title': 'Executive Director of Investor Relations & Corporate Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Michael J. Purvis', 'title': 'Executive VP, General Counsel & Corporate Strategy and Secretary', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Kevin J. Gilbert CPA, J.D.', 'title': 'Executive Vice President of Corporate Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Domingo  Rodriguez M.D.', 'age': 61, 'title': 'Executive Vice President of Global Clinical Operations', 'yearBorn': 1962, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Gary  Bird Ph.D.', 'title': 'Executive Vice President of Quality & Regulatory Affairs', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jason  Davies', 'title': 'Executive VP and GM of UK, Europe, EMEA, LATAM & ASPAC', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§10
boardRisk§8
compensationRisk§10
shareHolderRightsRisk§4
overallRisk§9
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
exDividendDate§1398643200
payoutRatio§0.0
fiveYearAvgDividendYield§3.71
beta§-0.248
priceToSalesTrailing12Months§5.260278
currency§USD
dateShortInterest§1702598400
forwardEps§-0.39
pegRatio§-0.01
exchange§NCM
quoteType§EQUITY
shortName§Veru Inc.
longName§Veru Inc.
firstTradeDateEpochUtc§918743400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§89add2fa-4457-393d-9280-b0ed7e5dccbe
gmtOffSetMilliseconds§-18000000
targetHighPrice§7.0
targetLowPrice§1.0
targetMeanPrice§3.33
targetMedianPrice§2.0
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§3
quickRatio§0.697
grossMargins§0.46425
ebitdaMargins§0.0
trailingPegRatio§None
